Hahn & Co, a South Korean private equity firm, has reached an agreement to acquire all remaining shares of Lutronic, a maker of aesthetic medical devices, for 957.0 billion South Korean won ($735.9 million). Lutronic, founded in 1997, reported revenues of over $207.5 million in 2022 and boasts a significant presence in the U.S. and Europe. This investment marks Hahn & Co's 34th investment in Korean businesses, with a total investment portfolio exceeding $27 billion.
In summary, South Korea's Hahn & Co. has signed definitive agreements to acquire Lutronic, a leading global aesthetic medical device manufacturer, for $735.9 million. Lutronic, established in 1997, has a strong presence in the U.S. and Europe and generated revenues of over $207.5 million in 2022. This transaction further expands Hahn & Co's investment portfolio, which now exceeds $27 billion.